The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

Background: In patients stabilized during hospitalization for acute decompensated heart
failure (HF), initiation of sacubitril/valsartan compared with enalapril decreased the risk of …

Background: Sacubitril/valsartan significantly reduced heart failure (HF) hospitalisations and
mortality in the PARADIGM-HF-trial. However real-world data on symptomatic and functional …

One of the defining features of heart failure (HF) is neurohormonal activation. The renin-
angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause …

Heart failure (HF) represents a widespread health problem characterized by high morbidity
and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients …

Background Impaired renal function is frequently observed in patients with heart failure and
reduced ejection fraction (HFrEF). The differential effect of sacubitril/valsartan and …

Background Sacubitril‐valsartan, an inhibitor of the angiotensin receptor neprilysin (ARNi),
has been purported to exhibit superiority over angiotensin converting enzyme (ACE) …

Background Sacubitril/valsartan (S/V) is indicated for the treatment of chronic heart failure
with reduced ejection fraction (HFrEF). The TRANSITION study aims to provide evidence of …

Background. Heart failure with reduced ejection fraction (HFrEF) is a heterogeneous
syndrome. In heart failure (HF) classifications, right ventricle (RV) function was for a long …

Background Correct classification of chronic heart failure (CHF) patients by dual evidence of
congestion and adequate perfusion is the primary clinical focus for management. Objectives …